HIV/AIDS Topics AIDS 2012: Does Hormonal Contraception Increase the Risk of HIV Infection?
- Details
- Category: HIV Prevention
- Published on Friday, 27 July 2012 00:00
- Written by Gus Cairns
The 19th International AIDS Conference (AIDS 2012) heard further contradictory evidence this week on whether hormonal contraceptives, especially injectable ones, raise the risk to women of acquiring HIV and, if they already have HIV, of developing AIDS.
Coverage of the XIX International AIDS Conference
- Details
- Category: HIV Treatment
- Published on Friday, 27 July 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the XIX International AIDS Conference (AIDS 2012), July 22-27 in Washington, DC.
Conference highlights include experimental antiretroviral drugs, treatment as prevention and PrEP, scaling up HIV treatment and prevention in resource-limited countries, human rights and concerns of heavily impacted populations, AIDS policy and advocacy, HIV/HBV and HIV/HCV coinfection, and the search for a cure for HIV.
HIVandHepatitis.com AIDS 2012 conference section
FDA Approves Truvada PrEP for Prevention of Sexually Transmitted HIV Infection
- Details
- Category: HIV Prevention
- Published on Monday, 16 July 2012 00:00
- Written by Liz Highleyman
On July 16, 2012, the U.S. Food and Drug Administration (FDA) approved Truvada -- Gilead Sciences' tenofovir/emtricitabine combination pill -- for pre-exposure prophylaxis (PrEP) to prevent sexual transmission of HIV.
NEXT-PrEP Trial Will Test CCR5 Blocker Maraviroc for HIV Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 20 July 2012 00:00
- Written by Press Release
The National Institutes of Health (NIH) this week announced a new clinical trial to assess whether taking the CCR5 antagonist maraviroc (Selzentry) daily -- alone or with other antiretroviral drugs -- can help lower the risk of HIV infection.
HIV PrEP Can Be Highly Effective, but Only if Used Consistently
- Details
- Category: HIV Prevention
- Published on Friday, 13 July 2012 00:00
- Written by Liz Highleyman
Pre-exposure prophylaxis (PrEP) with tenofovir or Truvada can dramatically lower the risk of HIV sexual transmission for heterosexual men and women -- as has previously been shown for gay men -- but good adherence is crucial to its success, according to a trio of studies published in the July 11, 2012, advance online edition of the New England Journal of Medicine.
Web Design and Development by